Notice Number: NOT-HL-18-665
Key Dates
Release Date: December 21, 2018
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The purpose of this Notice is to inform potential applicantsthat the National Heart, Lung, and Blood Institute (NHLBI) will participate, effective immediately, in PAR-18-966 "Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools(R15 Clinical Trial Required)".
The following sections of PAR-18-966 have been updated to reflect the participation of NHLBI in this Funding Opportunity Announcement (FOA):
Part 1. Overview InformationComponents of Participating Organizations
National Cancer Institute (NCI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Heart, Lung, and Blood Institute(NHLBI)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.393, 93.394, 93.395, 93.399, 93.865, 93.279, 93.173, 93.242, 93.853,93.837, 93.838, 93.839, 93.840, 93.233
Section VII. Agency Contacts
Scientific/Research Contact(s)
Aaron D. Laposky, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7837
Email: laposkya@nhlbi.nih.gov
Anthony Agresti
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0186
Email:agrestia@nhlbi.nih.gov
Inquiries
Please direct all inquiries to:
Aaron D. Laposky, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7837
Email: laposkya@nhlbi.nih.gov